Lanreotide: what Somatuline Depot labeling actually covers

The Somatuline Depot label lists long-term treatment of certain patients with acromegaly, treatment of selected unresectable or advanced gastroenteropancreatic neuroendocrine tumors to improve progression-free survival, and treatment of adults with carcinoid syndrome. These are different clinical goals. FDA’s generic-approval list also identifies the reference indications, but the current label is the best source for precise wording. DailyMed: Somatuline Depot current label FDA: 2024 generic drug approvals

Lowering growth-hormone measures in acromegaly, delaying tumor progression in a defined cancer population, and reducing need for rescue therapy in carcinoid syndrome are not the same endpoint. Ask which diagnosis and outcome the treating specialist is addressing. AHRQ’s evidence framework requires population, intervention, comparison, and outcome because a result from one condition does not support another. DailyMed: Somatuline Depot current label AHRQ: Systematic review methods

The label includes contraindications, warnings, and adverse reactions; the clinician should interpret them alongside the patient’s other care. A broad “hormone balance” pitch omits the named conditions and monitoring in the approved label. FDA’s labeling FAQ helps patients locate prescribing and patient information. Do not use this article to choose a dose or treatment interval. DailyMed: Somatuline Depot current label FDA: Labeling FAQ for prescription medicines

An approved lanreotide product demonstrates that some peptides have rigorous product-specific approvals. It does not establish that a clinic’s unrelated peptide service provides Somatuline Depot. Nor does it confer approval on a compounded preparation. Patients with these diagnoses should coordinate treatment access and monitoring through the appropriate specialist team. FDA: Compounding and the FDA Q&A

For a defined tumor population, delaying measured progression is a meaningful study endpoint but is not automatically the same as curing cancer or extending survival for every patient. Ask the oncologist how the trial population compares with the individual case and which scans or symptoms will guide follow-up. The label’s exact language matters because a promotional summary can blur treatment goal and expected outcome. DailyMed: Somatuline Depot current label

In acromegaly, the label names growth hormone and IGF-1 reduction as treatment goals in patients with limited surgical or radiation options. That does not make lanreotide a general hormone-balancing treatment. Ask which measure establishes disease control and which adverse effects warrant monitoring. A single peptide class word cannot capture these separate specialist decisions. DailyMed: Somatuline Depot current label

If another clinician reviews your medicine list, include Somatuline Depot rather than only “lanreotide peptide.” This avoids confusion with other products and makes it easier to review the relevant label and adverse effects. Bring the oncology or endocrine team’s monitoring plan to urgent visits when possible. Product specificity is a practical safety tool as well as an evidence principle. FDA: Labeling FAQ for prescription medicines